StockData
Satellos Bioscience Inc. logo

Satellos Bioscience Inc. (MSLE) stock

MSLENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 40-F on Mar 27, 2026Score 5/30
$6.63−0.21 (-3.00%)

Close on Nov 13, 2026Market cap $102.42MP/E –Yield –

Earnings

Satellos Bioscience's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Satellos Bioscience's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Satellos Bioscience has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Satellos Bioscience puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Satellos Bioscience filed with the SEC as exhibits to Form 8-K or 6-K

  1. Condensed Consolidated Interim Financial Statements
    6-K
  2. For the three months and nine months ended September 30, 2026, and 2025
    6-K
  3. Satellos Reports Third Quarter 2026 Financial Results and Highlights Company Progress
    6-K
  4. Satellos Changes Primary Efficacy Endpoint in BASECAMP Phase 2 Pediatric Trial to MRI-Measured Fat Fraction Following FDA Feedback
    6-K
  5. Satellos to Host Investor Call to Provide an Update on Clinical and Regulatory Strategy for the BASECAMP Phase 2 Pediatric Study
    6-K
  6. Satellos Establishes Scientific Advisory Board to Explore the Biology of Regeneration in Aging and Neuroscience
    6-K
  7. Satellos to Participate in Upcoming Investor Conferences
    6-K
  8. Satellos Granted Composition of Matter Patent for Forazapadin
    6-K
  9. Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy
    6-K
  10. 6-K exhibit EX-99.1
    6-K
  11. Satellos to Present at the 31st Annual Congress of the World Muscle Society
    6-K
  12. Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247
    6-K
  13. Satellos to Participate in Upcoming Investor Conferences
    6-K
  14. 6-K exhibit EX-99.1
    6-K
  15. Condensed Consolidated Interim Financial Statements
    6-K

See a number that looks wrong?